Back

Optimization of velocity receptor transduction in CAR T cells

Jiang, X.; Queiroga, V.; Hanna, E. A.; Wirtz, D.

2025-10-06 bioengineering
10.1101/2025.10.05.680548 bioRxiv
Show abstract

Limited infiltration capacity significantly limits the effectiveness of chimeric antigen receptor (CAR) T cells for solid tumors. We have recently developed a large family of highly modular synthetic cytokine receptors termed velocity receptors (VRs), capable of binding key inflammatory cytokines, such as IL5, IL8, and TNF, which drive CAR T cells into an elevated motility state. These new CAR T cells sense and amplify these autocrine secreted cytokines, thereby maintaining a self-propelled, high migratory state, facilitating penetration into dense tumor cores. In this study, we systematically evaluated key factors influencing VR transduction in order to improve their stable integration and expression. We established a dual-fluorescence reporter system to allow simultaneous monitoring of both VR and CAR constructs, and while evaluating modifications to the vector construct and generating standardized infectious unit (IFU) curves under various conditions. Our results demonstrate that the attempt to reduce overall lentiviral vector size by eliminating non coding sections upstream of the central polypurine tract (cPPT) do not yield better transduction efficiency, though it is unclear if the effect is due to viral production or integration impairment. We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5IL8 and VR5TNF VRs consistently outperforming VR5IL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

1
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
51.4%
50% of probability mass above
2
Molecular Therapy
81 papers in training set
Top 0.4%
4.6%
3
Viruses
332 papers in training set
Top 1%
4.2%
4
Scientific Reports
3612 papers in training set
Top 37%
3.1%
5
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.3%
3.1%
6
Cell Reports Methods
165 papers in training set
Top 1%
2.3%
7
Bioengineering & Translational Medicine
21 papers in training set
Top 0.2%
2.3%
8
Nature Communications
5641 papers in training set
Top 46%
1.7%
9
ACS Synthetic Biology
287 papers in training set
Top 1%
1.6%
10
PLOS ONE
5266 papers in training set
Top 52%
1.4%
11
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 1%
1.3%
12
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
1.3%
13
Cellular and Molecular Bioengineering
22 papers in training set
Top 0.3%
1.3%
14
Analytical Chemistry
218 papers in training set
Top 2%
1.3%
15
Vaccines
198 papers in training set
Top 3%
1.1%
16
Molecular Therapy - Nucleic Acids
25 papers in training set
Top 0.6%
0.9%
17
Biotechnology and Bioengineering
53 papers in training set
Top 1.0%
0.8%
18
Journal of Virology
499 papers in training set
Top 3%
0.8%
19
Journal of Visualized Experiments
34 papers in training set
Top 0.6%
0.8%
20
iScience
1154 papers in training set
Top 37%
0.8%
21
Journal of Biological Engineering
12 papers in training set
Top 0.1%
0.8%
22
Molecular Pharmaceutics
16 papers in training set
Top 0.4%
0.8%
23
Molecular Therapy Oncology
10 papers in training set
Top 0.3%
0.8%
24
The FASEB Journal
194 papers in training set
Top 6%
0.8%
25
NAR Cancer
37 papers in training set
Top 0.8%
0.8%
26
npj Vaccines
67 papers in training set
Top 0.8%
0.8%